WuXi Vaccines' First Drug Substance Facility in China Released for GMP Manufacturing

Mr. Jian Dong, CEO of WuXi Vaccines, commented, "The release of the drug substance facility at our Suzhou site and the start of manufacturing marks a major milestone for WuXi Vaccines. Leveraging our expertise, advanced facilities, and innovative technology platforms, while adhering to global cGMP standards and regulatory guidelines, we are primed to meet the rising demand for vaccine development and manufacture, and advance the availability of safe and effective vaccines worldwide." Mr...
Comunicato Precedente

next
Comunicato Successivo

next
Preferisci Informazione.News su Google

Mr. Jian Dong, CEO of WuXi Vaccines, commented, "The release of the drug substance facility at our Suzhou site and the start of manufacturing marks a major milestone for WuXi Vaccines. Leveraging our expertise, advanced facilities, and innovative technology platforms, while adhering to global cGMP standards and regulatory guidelines, we are primed to meet the rising demand for vaccine development and manufacture, and advance the availability of safe and effective vaccines worldwide."

About WuXi Vaccines

WuXi Vaccines is a leading contract development and manufacturing organization (CDMO) that focuses on vaccine development and manufacturing. It provides world-class integrated development and manufacturing platforms to expedite partners' vaccines to the clinical stage and the market, regardless of the vaccine modality (i.e., protein, virus, VLP, DNA, mRNA/RNA). With its technical expertise, broad regulatory knowledge, premium quality system, advanced CMC development capabilities, multiple production platforms (mammalian, microbial), and extensive GMP manufacturing capacities, WuXi Vaccines provides an end-to-end service – from vaccine discovery and development to large-scale commercial production and distribution. The company can enable any global partner to deliver critical vaccines anywhere in the world, making it an essential partner in protecting public health. For more information about WuXi Vaccines, please visit: https://wuxivaccines.com.

Contacts

Business
WuXiVaccines@wuxibiologics.com

Media
PR@wuxibiologics.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/wuxi-vaccines-first-drug-substance-facility-in-china-released-for-gmp-manufacturing-301887654.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili
;